NRx Pharmaceuticals has seen its share price under pressure in recent years, which naturally puts the spotlight on what investors are paying for its current sales base. The open question is whether the recent trading level around US$2.15 a share can be squared with the revenue the business is generating today.
For investors, the debate is whether the current US$2.15 share price is adequately supported by NRx Pharmaceuticals' sales when judged against the Fair Ratio benchmark.
If you want a wider set of ideas while you assess whether NRx Pharmaceuticals' sales justify its current price, a focused stock screen built around 35 high quality undervalued stocks can help broaden your research universe.
P/S fits NRx Pharmaceuticals because the business is currently more about its revenue base than bottom line earnings. On this yardstick the stock trades on a P/S of 27.4x, versus roughly 4.1x for the wider Pharmaceuticals sector and about 20.6x for closer peers. That is a steep step up in what investors are paying for each dollar of sales compared with both the broader group and more similar companies.
The Fair Ratio framework, which adjusts for factors like margins, scale, risk and expected cash generation, indicates that this P/S level screens as overvalued. The gap is so wide that the model is effectively flagging how heavily the current share price leans on future execution rather than treating the output as a precise target. Anyone weighing NRx Pharmaceuticals at today’s valuation needs to judge whether the quality and durability of its revenue opportunity really justify such a premium to both the sector and peer set. Explore the numbers behind NRx Pharmaceuticals's P/S valuation.
Narratives for NRx Pharmaceuticals pick up where the valuation question stops and spell out the future conditions on growth, margins and earnings that would need to hold for the stock to be priced meaningfully higher or lower than it is today on Simply Wall St's Community page. Instead of a single ratio or model output, they unpack the business path that number implies so you can watch over time whether reality is matching that script.
One of the top narratives on NRx Pharmaceuticals: 96% undervalued
This Narrative is the analyst consensus Narrative on Simply Wall St, which compiles analysts' consensus price target and revenue and earnings forecasts, not one person's view.
"The build out of HOPE Therapeutics clinics, already generating revenue from ketamine and TMS sessions and targeting multi modality, shorter course treatments, ties NRx directly into reimbursed care pathways…"
Discover why this Narrative puts NRx Pharmaceuticals at 96% undervalued.
Current multiples tell you what investors are paying today, but the analyst view a few years out offers a different lens on what they think this business could look like tomorrow. Explore where analysts expect NRx Pharmaceuticals to be in a few years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com